Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Investor Presentation (February 2025)
22 slides from Marinomed Biotech's investor presentation, February 2025
Slide 1: Marinomed Biotech AG Corporate Presentation
Marinomed Biotech AG Corporate Presentation February 2025
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Company
Company Equity Story, Overview, Business Model
Slide 4: Equity Story
Equity Story Becoming the top innovator for respiratory and ophthalmic solutions. Experienced management team Andreas Eva Prieschl- Gabriele Ram Clinically proven potential disruptive technology Grassauer Grassauer Chief Financial Chief Executive Chief Scientific Officer Officer Officer Late-stage a
Slide 5: Marinomed at a glance
Marinomed at a glance Publicly listed biopharmaceutical company located in Korneuburg, Austria 15 Revenue, EBIT and R&D spending (€m) 11.6 11.3 9.2 Revenue 10 8.1 * * 6.1 ** EBIT * 5 R&D expenses 0 * Revenue driven by pandemic impact -5 ** Including € 1.9m -4.1 -4.9 milestone -4.8 -5.8 -5.1 -6.2 -6.
Slide 6: Business Model
Business Model Development phase OTC (over-the-counter) Rx (prescription) Idea & preclinical research Generation of Early clinical development intellectual property Late clinical development Market authorization Manufacturing Commercialization Distribution & marketing through partners Vigilance Mari
Slide 7: Technologies & Pipeline
Technologies & Pipeline Q Marinomed
Slide 8: Technologies & Therapeutic Areas
Technologies & Therapeutic Areas Universal blocking of viruses and allergens as well as Solubilization of poorly water-soluble compounds and moistening of mucosal tissues improving local onset of action Cough & cold Allergy Eye drops Budesolv Tacrosolv Solv4U portfolio* nasal spray* Dry, irritated A
Slide 9: Pipeline
Pipeline Including late-stage projects with low risk and meaningful upside potential Pharmaceutical Products Therapeutic Product Status Pre-clinical Phase I Phase II Phase III Filing Area Indication MAM-1004-1/Budesolv Filing in Treatment of severe allergic rhinitis preparation IMMUNOLOGY MAM-1003-1
Slide 10: Carragelose®
Carragelose® Universal blocking of viruses and allergens as well as moistening of mucosal tissues Assets • Virus-blocking OTC product portfolio • Partnered in >40 countries • MAM-1001-4 nasal spray Without Carragelose: With Carragelose: • First launch in Austria (April 2024) Virus / allergens intera
Slide 11: Carragelose® OTC portfolio
Carragelose® OTC portfolio Revenue-generating product portfolio targeting cough/cold, hayfever, and dry eyes Extensive clinical data1 Partnering • Forms non-specific, moisturizing layer that protects mucosa • Nasal sprays, throat spray, lozenges & eye drops from viruses & allergens and provides reli
Slide 12: Carragelose®
Carragelose® Universal blocking of viruses and allergens as well as moistening of mucosal tissues Recent developments Next steps • Received MDR certificates for first Carragelose products • Transfer Carragelose portfolio to Unither Pharmaceuticals and support via transition service • Completed clini
Slide 13: Marinosolv
Marinosolv Solubilization of poorly water-soluble compounds - improving local onset of action Assets • MAM-1004-1/Budesolv: • Solubilized budesonide for treating allergic rhinitis • Post-phase-III • MAM-1003-1/Tacrosolv: Aqueous formulation of hardly Marinosolv formulation of • Solubilized tacrolimu
Slide 14: Budesolv: anti-allergic product post phase III
Budesolv: anti-allergic product post phase III The first low-dose, preservative-free nasal steroid with strong symptom relief after first dose Budesolv → fully solubilized Budesonide (corticosteroid) targeting Next steps: allergic rhinitis • Add further partnerships in 2024 ✓ Onset of action in hour
Slide 15: Tacrosolv: targeting ocular inflammation
Tacrosolv: targeting ocular inflammation Novel low-dose, preservative-free eye drops post-phase II Tacrosolv → fully solubilized Tacrolimus (immunosuppressor) Next steps: targeting anterior inflammatory eye diseases and beyond ✓ Increased bioavailability in cornea and conjunctiva • Late-stage clinic
Slide 16: Solv4U overview
Solv4U overview Solubilization technology partnerships based on Marinosolv® PHASE I PHASE II PHASE III PHASE IV FEASIBILITY FORMULATION PRECLINICAL & TECH TRANSFER DEVELOPMENT CLINICAL STUDIES Enhanced solubility of target Optimize formulation & Provide Target Product Profile (TPP) & Enable manufact
Slide 17: Financials
Financials H1 2024* *Selected, preliminary H1 figures - Publication of the half-year financial report 2024 planned after the three-month restructuring phase
Slide 18: H1 2024: Preliminary figures
H1 2024: Preliminary figures* All amounts in € thousand H1 2024* H1 2023 Revenues • Revenues for Q2 2024 at € 1.7m (Q1 2024: € 0.7m) Revenues 2,463.9 5,228.5 • Revenues include milestone from new European contract Operating result (EBIT) -3,225.3 -2,906.4 • Order intake currently on pre-pandemic lev
Slide 19: Outlook
Outlook Q Marinomed
Slide 20: Preparing for long-term perspective
Preparing for long-term perspective Turning innovation into revenue as basis for the continuation of the Company Conclude license Sale of Carragelose Expand Solv4U technology agreements for Budesolv & portfolio partnerships & services Tacrosolv Focus on generating near-term cash flows & successful c
Slide 21: Financial calendar & IR contact
Financial calendar & IR contact Financial Calendar 2025 Publication of the Annual Financial Report and 16.04.2025 Sustainability Report 2024 Record Date for Participation at the 8th Annual General 01.06.2025 Meeting 11.06.2025 8th Annual General Meeting 17.09.2025 Publication of the Half-Year Financ
Slide 22: www.marinomed.com
www.marinomed.com 0) Marinomed
Marinomed Biotech — Investor Presentation (February 2025) on 6ix